Benefits
Depression
5-HTP may alleviate depressive symptoms by increasing serotonin levels in the brain. Some studies, particularly in Parkinson’s disease patients or those with mild depression, show modest improvements in mood, though results are inconsistent and often comparable to placebo effects (30–45% response rate).
Sleep Improvement
By boosting serotonin, which is converted to melatonin, 5-HTP may improve sleep quality, particularly in older adults or poor sleepers. Clinical trials have shown reduced sleep latency and better Pittsburgh Sleep Quality Index (PSQI) scores with doses of 100–200 mg/day.
Fibromyalgia
5-HTP may reduce pain, fatigue, and tender point sensitivity in fibromyalgia patients. A 1990 trial showed significant symptom improvement with 300 mg/day, likely due to enhanced serotonin signaling.
Weight Management
5-HTP may promote weight loss by increasing satiety and reducing appetite, particularly carbohydrate intake. Earlier studies in obese adults used 900 mg/day with significant weight loss; a more recent 8-week RCT in resistance-trained adults found 100 mg/day reduced fat mass without changing food intake — suggesting effects on body composition may occur even at lower doses. Long-term efficacy data limited.
Migraine Prophylaxis
5-HTP at up to 300 mg/day showed comparable efficacy to methysergide (a serotonergic migraine prophylactic) in a 124-patient RCT, with lower side-effect burden. 5-HTP appeared most effective at reducing attack intensity and duration rather than frequency. Older RCTs and an open Italian trial support its use in migraine prophylaxis.
Gut Health
Preliminary research suggests 5-HTP may enhance gut microbiota diversity and short-chain fatty acid production, potentially benefiting overall health, though this is a newer area of study.
Mechanism of action
Neurotransmitter Modulation
Elevated serotonin levels enhance signaling through serotonin receptors (e.g., 5-HT1A, 5-HT2C), which are involved in mood regulation, anxiety reduction, and satiety. This underlies 5-HTP’s potential benefits for depression, fibromyalgia, and weight management. Serotonin produced from 5-HTP is a precursor to melatonin in the pineal gland, promoting sleep onset and quality by regulating circadian rhythms.
Central and Peripheral Effects
Unlike serotonin, 5-HTP crosses the blood-brain barrier, increasing CNS serotonin synthesis. Peripherally, it may influence gut motility and microbiota by boosting serotonin in enterochromaffin cells, potentially affecting gut health.
Anti-Inflammatory and Pain Modulation
In conditions like fibromyalgia, 5-HTP’s serotonin-boosting effects may modulate pain perception by enhancing descending inhibitory pathways in the CNS, reducing sensitivity to pain signals.
Appetite Suppression
5-HTP may activate serotonin receptors (e.g., 5-HT2C) in the hypothalamus, increasing feelings of fullness and reducing carbohydrate cravings, which supports its use in weight management.
Clinical trials
Single-center, randomized, double-blind, placebo-controlled crossover trial in 25 patients with Parkinson's disease and depression/apathy. Patients received 50 mg/day 5-HTP or placebo for 4 weeks each, with assessments via Hamilton Depression Rating Scale (HDRS), Beck Depression Inventory-II (BDI-II), and Apathy Scale (AS). (Meloni et al. 2020)
25 patients with Parkinson's disease. 4-week crossover.
5-HTP significantly improved depressive symptoms vs placebo (HDRS reduction, p<0.05) but showed no effect on apathy (AS scores). No serious adverse events. Provides preliminary evidence for 5-HTP in PD-related depression but emphasizes need for larger trials.
Double-blind, placebo-controlled trial in 50 patients with primary fibromyalgia syndrome. Patients received 100 mg 5-HTP three times daily (300 mg/day) or placebo for 30 days. Outcomes: pain intensity, sleep quality, fatigue, and tender point count. (Caruso et al. 1990)
50 patients with primary fibromyalgia syndrome. 30-day intervention.
5-HTP significantly improved pain, sleep quality, fatigue, and tender point scores compared to placebo (p<0.05). Side effects were mild and transient (mild nausea, heartburn). Suggests 5-HTP may benefit fibromyalgia symptoms; further controlled studies needed.
Single-blinded, 12-week parallel randomized controlled trial in 30 older adults (mean 66 years) in Singapore. Participants received 100 mg/day 5-HTP or no supplementation. Sleep quality assessed via Pittsburgh Sleep Quality Index (PSQI) and actigraphy; serum serotonin, urine melatonin, and 16S gut microbiota also measured. (Sutanto et al. 2024)
30 older adults (mean age 66). 12-week intervention.
5-HTP improved sleep quality (PSQI scores) particularly in poor sleepers (GSS>5), increased serum serotonin, and improved gut microbiota α-diversity and SCFA-producing bacteria abundance. Effects most prominent in subjects with baseline poor sleep status. No significant adverse events.
Randomized clinical trial in 124 migraine patients comparing 5-HTP (up to 300 mg/day) vs. methysergide (up to 6 mg/day). Outcomes: migraine frequency, intensity, and duration. (Titus et al. 1986)
124 migraine patients. Open-label randomized comparison.
Significant improvement was observed in 75% of methysergide patients and 71% of 5-HTP patients. 5-HTP showed strongest effects on attack intensity and duration rather than frequency. Side effects were less frequent in 5-HTP group. Authors concluded 5-HTP could be a treatment of choice for migraine prophylaxis.
Randomized, placebo-controlled, double-blind trial in 48 resistance-trained adults. Participants received 100 mg/day 5-HTP (CLEANMOOD™) or placebo (maltodextrin) for 8 weeks. Body composition assessed by multi-frequency bioelectrical impedance (InBody® 270). (Evans et al. 2022)
48 resistance-trained adults (31 5-HTP, 17 placebo). 8-week intervention.
Fat mass decreased significantly in the 5-HTP group (p=0.02) but not in placebo (p=0.58); between-group difference was significant (p=0.048). Lean body mass and total body water did not change significantly. No significant changes in food intake, suggesting effect was not driven by appetite suppression.
Systematic review and meta-analysis (PRISMA-guided, PROSPERO pre-registered) of 13 studies in the systematic review and 7 in the meta-analysis assessing 5-HTP for depression. Doses ranged 50–600 mg/day across various depression types. (Javelle et al. 2020, Nutrition Reviews)
13 investigations included; 7 in full meta-analysis.
Depression remission rate of 0.65 (95% CI: 0.55–0.78), with large Hedges' g=1.11 (95%CI: 0.53–1.69). Significant methodological variability (I²=76%) due to differences in treatment duration, depression type, design, and dosing. Concludes 5-HTP shows antidepressant effects but heterogeneity limits firm recommendations.